Pharmacies are getting a bad name when price myopia is the real culprit
A recent New York Times article took aim at pharmacies, but the major problem going unresolved is price myopia.
Most recent articles by Sander A. Flaum
The next big thing in pharma might not be something you like
Hospitals competing on pharma’s turf by supplying their own generics signals a tectonic shift, and don’t expect it to go away anytime soon.
Forget about pharma profits and focus on drug tort reform
While many critics are quick to point to a pharma company’s profits, you don’t hear enough about the money being made by the drug tort industry.
It’s time to push back on drug price legislation
Sander Flaum wants pharma to push back on pricing legislation.
Want to save money on drug prices? Don’t listen to Washington
Sander Flaum urges Americans to ignore politicians’ calls to head north of the border for their prescription medication.
Healthcare system won’t be fixed by lower drug prices alone
Even if drug manufacturers lower prices, it won’t fix the U.S healthcare system.
Was President Trump’s plan to reduce drug prices DOA?
President Trump’s blueprint to lower drug prices hasn’t made it out of the brainstorm phase.
Critics who want to cut drug prices must say which ones
Cutting prescription drug prices has become one of the most popular campaign promises of our time.
Paying Lip Service to STEM Isn’t Enough
I’m not suggesting that colleges become vocational schools. But don’t you think they should also help young people prepare for the life they’re going to be living?
Will Investors Reward Drugmakers That Limit Price Increases?
Now here comes the big question. Will the shareholders and directors of KaloBios and Allergan reward or punish their CEOs for what some may see as revenue-capping concessions?
